



FOR IMMEDIATE RELEASE

SK Biopharmaceuticals Partners with Cala to Fuel Innovation in Neurology

SK Biopharmaceuticals invests with SK Inc. in Cala Health, a Silicon Valley based bioelectronic medicine leader

SK Biopharmaceuticals' strategic partnership with Cala Health opens up the potential to explore solutions for new indications in neurology

Pangyo, Gyeonggi Province, Korea, May 19, 2022 – SK Biopharmaceuticals, Co., Ltd. announced that together with its parent investment company SK Inc., the two companies have participated in a Series D funding for Cala Health, a U.S. bioelectronic medicine leader.

This marks the first time for SK Biopharmaceuticals to invest in the space, paving the way for further strategic partnership and investment in the world's largest biotech and healthcare market.

SK Biopharmaceuticals said its investment in Cala Health will offer opportunities for potential technology collaboration with the U.S. company in the new neurological space. This will also be a "stepping stone" for the company to further drive innovation in patient access and care.

SK Biopharmaceuticals is currently developing a digital therapeutic device that can detect seizures for patients with epilepsy. This is expected to enter a clinical trial at the end of this year and be previewed at the CES exhibition in Las Vegas next year.

Cala Health is the leader in non-invasive bioelectronic therapy via Cala Trio™, a wearable device cleared by the US Food and Drug Administration that is proven to reduce essential tremors and improve patients' quality of life.

"We are pleased a global leader like SK Biopharmaceuticals and SK Inc. have chosen Cala as their first U.S. digital healthcare investment partner" said Renee Ryan, CEO of Cala. "Together, we will accelerate the realization of our joint mission of developing treatments and driving innovation to help more patients struggling with neurologic disorders."

"We are excited to forge a strategic partnership with Cala Health in bioelectronic medicine, and further support our common goal of spurring innovation and improving patients' lives. SK Biopharmaceuticals will work closely with Cala and global partners as we seek to provide total healthcare solutions to patients and their loved ones," said Dr. Jeong Woo Cho, CEO of SK Biopharmaceuticals and SK life science.

About SK Biopharmaceuticals Co., Ltd. And SK Life Science, Inc.

SK Biopharmaceuticals and its U.S. subsidiary SK life science are pharmaceutical companies focused on the global research, development, and commercialization of treatments for disorders of the central nervous system (CNS). The companies have two approved medicines and a diverse pipeline of compounds in development for the treatment of CNS disorders, including epilepsy. Additionally, SK Biopharmaceuticals is focused on the discovery of new treatments in oncology. For more information, visit SK Biopharmaceuticals' website at

www.skbp.com/eng and SK life science's website at www.SKLifeScienceInc.com.

About Cala

Cala is a bioelectronic medicine company transforming the standard of care for chronic disease. The company's wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation, and its vertically integrated commercial model is reshaping the delivery of prescription therapies. Cala's lead product, Cala Trio™, is the only non-invasive prescription therapy for essential tremor. New therapies are under development in Parkinson's disease and other indications in neurology, as well as targets in psychiatry, cardiology and autoimmune disorders. The company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology.

Cala Trio is indicated to aid in the transient relief of hand tremors in the treated hand following stimulation in adults with essential tremor. Please refer to the Safety Information [<https://calatrio.com/#SafetyInformation>] for a complete listing of warnings and cautions.

Media Inquiries

SK Biopharmaceuticals
Hyongki Park, Director of Communications
h.p.comm@sk.com

Jaehee Kang, Communications Manager
jaeheekang@sk.com